STOCK TITAN

Ardelyx (ARDX) Chief Patient Officer sells shares, exercises 31,000 options

Filing Impact
(Very High)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

Ardelyx, Inc. Chief Patient Officer Laura A. Williams reported an open-market sale of 81,898 shares of common stock at a weighted average price of $5.989 per share. The sale was made pursuant to a Rule 10b5-1 trading plan adopted on March 19, 2026, and the trades occurred in a price range from $5.97 to $6.0086. Following the sale, Williams directly holds 378,195 shares of Ardelyx common stock. On the same date, she also exercised a stock option to acquire 31,000 shares at an exercise price of $0.99 per share, reducing the outstanding option grant tied to those shares.

Positive

  • None.

Negative

  • None.
Insider Williams Laura A
Role Chief Patient Officer
Sold 81,898 shs ($490K)
Type Security Shares Price Value
Exercise Stock Option (Right to Buy) 31,000 $0.00 --
Exercise Common Stock 31,000 $0.99 $31K
Sale Common Stock 81,898 $5.989 $490K
Holdings After Transaction: Stock Option (Right to Buy) — 31,000 shares (Direct, null); Common Stock — 460,093 shares (Direct, null)
Footnotes (1)
  1. Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 19, 2026. Transaction was executed in multiple trades in prices ranging from $5.97 to $6.0086, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. The option becomes exercisable as it vests and the shares subject to the option vest in 48 successive, equal monthly installments on each monthly anniversary of January 6, 2022, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date.
Shares sold 81,898 shares Open-market sale of Ardelyx common stock
Sale price $5.989 per share Weighted average sale price for the transaction
Post-sale holdings 378,195 shares Direct Ardelyx common stock held after transactions
Options exercised 31,000 shares Common shares acquired via stock option exercise
Option exercise price $0.99 per share Strike price of exercised stock option
Sale price range $5.97–$6.0086 per share Range of individual trade prices within the sale
Rule 10b5-1 trading plan regulatory
"Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
open-market sale financial
"transaction_action: open-market sale"
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.
Stock Option (Right to Buy) financial
"security_title: Stock Option (Right to Buy)"
derivative security financial
"transaction_code_description: Exercise or conversion of derivative security"
A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.
weighted average sale price financial
"The price reported ... reflects the weighted average sale price"
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Williams Laura A

(Last)(First)(Middle)
C/O ARDELYX, INC.
400 FIFTH AVENUE, SUITE 210

(Street)
WALTHAM MASSACHUSETTS 02451

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
ARDELYX, INC. [ ARDX ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
Chief Patient Officer
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/18/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock06/18/2026M(1)31,000A$0.99460,093D
Common Stock06/18/2026S(1)81,898D$5.989(2)378,195D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to Buy)$0.9906/18/2026M(1)31,000 (3)01/06/2032Common Stock31,000$031,000D
Explanation of Responses:
1. Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 19, 2026.
2. Transaction was executed in multiple trades in prices ranging from $5.97 to $6.0086, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
3. The option becomes exercisable as it vests and the shares subject to the option vest in 48 successive, equal monthly installments on each monthly anniversary of January 6, 2022, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date.
Remarks:
Exhibit 24.1 - Power of Attorney
/s/ Felecia Ettenberg, Attorney-in-Fact for Laura A. Williams06/22/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Ardelyx (ARDX) report for Laura A. Williams?

Laura A. Williams reported selling 81,898 Ardelyx shares. She executed an open-market sale of common stock at a weighted average price of $5.989 per share and remains a significant direct shareholder after the transaction.

At what prices did Laura A. Williams sell Ardelyx (ARDX) stock?

The reported weighted average sale price was $5.989 per share. Individual trades were executed in multiple transactions within a price range from $5.97 to $6.0086 per share, according to the disclosed footnote details.

How many Ardelyx (ARDX) shares does Laura A. Williams hold after the Form 4 transactions?

After the reported transactions, Williams holds 378,195 Ardelyx shares. This reflects her remaining direct ownership following the open-market sale of 81,898 shares of common stock disclosed in the filing.

Did Laura A. Williams exercise stock options in the latest Ardelyx (ARDX) Form 4?

Yes, she exercised options for 31,000 Ardelyx shares. The stock option carried an exercise price of $0.99 per share, converting derivative rights into additional common stock on the same date as the reported sale.

Was the Ardelyx (ARDX) insider sale by Laura A. Williams under a Rule 10b5-1 plan?

Yes, the sale was made under a Rule 10b5-1 trading plan. The plan was adopted on March 19, 2026, indicating the transactions were pre-arranged rather than newly decided at the time of execution.